Drug Development Programs
Ångstrom Has a Promising Drug Candidate, Å6, in Advanced Product Development
Å6 consistently shows efficacy across cancers and age-related macular degeneration (ARMD), indicating that it is addressing a fundamental pathway for proliferative and invasive diseases. The favorable biological activity of Å6 has been demonstrated in in vitro models of cell migration, invasion and angiogenesis, as well as in breast, prostate and brain tumor models. This activity has also been demonstrated in animal models of ocular disease.
Results from a completed Phase 1a safety clinical trial in humans showed there were no systemic drug-related adverse events in healthy volunteers. The Company has also successfully completed a Phase 1b clinical trial evaluating Å6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating Å6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with Å6 experienced disease stabilization.
ARMD Program
Å6 has also been shown to significantly reduce neovascular lesions in animal models. In addition to pursuing the use of Å6 for cancer, the Company is also investigating pre-clinical development of compounds for the intraocular treatment of ARMD.